Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TBC1 domain family member 3 pseudogene 4 (abbreviated *TBC1D3P4*) is classified as a **pseudogene** and is not considered a functional therapeutic target, receptor, enzyme, transporter, or signaling protein[1]. It is part of the larger TBC1D3 gene family, which includes several functional paralogs in humans, some of which have been implicated in cell proliferation and oncogenesis (especially in kidney and liver cancers) and have prognostic relevance[2][3][4]. However, *TBC1D3P4* itself does not encode a functional protein and is referred to as a pseudogene. The pseudogene also has the alias **USP6P2**[1]. There is no evidence in the literature of *TBC1D3P4* being a molecular target for drugs, disease modulation, or biomarker use, nor does it have known biological functions or safety concerns relevant to therapeutic development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TBC1 domain family member 3 pseudogene 4 (TBC1D3P4).